CK2 Inhibitors – New CK2 Kinase Inhibitors for antineoplastic drugs and diagnostics
Beside cardiovascular diseases, malignant tumours take
the second place in cause of human death. Neoplastic diseases are indicated by a high cell proliferation. The inhibition of this cell proliferation by an active agent in a medicament is a worldwide accepted approach for tumour therapy. Protein kinase CK2 belongs together with others to the group of second-messenger independent kinases. Despite of unambiguous references for the involvement of CK2 in malignant transformation, tumour origin and progression, there are only a few effective inhibitors for this enzyme on-hand. This invention provides access to a novel class of potent human CK2 kinase inhibitors. The disclosed compounds can be used as active ingredients e.g. for the treatment of neoplastic diseases. Further, the patent application discloses synthesis of the compounds with optimised product yield.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Combatting disruptive ‘noise’ in quantum communication
In a significant milestone for quantum communication technology, an experiment has demonstrated how networks can be leveraged to combat disruptive ‘noise’ in quantum communications. The international effort led by researchers…
Stretchable quantum dot display
Intrinsically stretchable quantum dot-based light-emitting diodes achieved record-breaking performance. A team of South Korean scientists led by Professor KIM Dae-Hyeong of the Center for Nanoparticle Research within the Institute for…
Internet can achieve quantum speed with light saved as sound
Researchers at the University of Copenhagen’s Niels Bohr Institute have developed a new way to create quantum memory: A small drum can store data sent with light in its sonic…
